Cimzia's Phase III Data First In Non-Radiographic Axial Spondyloarthritis

Top-line Phase III data suggests UCB Pharma's Cimzia has benefits in a specific type of axial spondyloarthrits, with the findings expected to be submitted to the US FDA in the coming months.  

Back pain
Lower back pain is a feature of axial spondyloarthritis • Source: Shutterstock

There is a lack of US FDA-approved therapies for non-radiographic axial spondyloarthritis, a deficit that UCB Group hopes to address with its marketed biologic therapy, Cimzia (certolizumab pegol), which is currently indicated for the related condition, ankylosing spondylitis, among a number of other indications.

The Belgium-headquartered multinational reported top-line results from the Phase III C-AXSPAND study on May 16, showing Cimzia met its primary...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip